Claudio obtained his PhD in Chemistry (Mechanisms of Organic Reactions) from the University of Rome in 2000. He went for a post-doc at Imperial College London where he worked on Alzheimer’s disease chemical probes. In 2004, he started working in several companies in the Cambridge biotech cluster where he deepened his knowledge in Medicinal Chemistry and in Fragment Based Drug Design. In 2012, he went back to academia at Cambridge University where he investigated challenging drug targets such as protein-protein interactions. He also co-founded the Entrepreneurial Postdocs of Cambridge (EPOC) society in 2015 to support postdocs in their pursuit of entrepreneurial careers. In 2017, joined Capital Cell with a role in Business Development, then Abzena in Cambridge and finally o2h in January 2021.